Hot Investor Mandate: Cross-Border Biotech Sector Fund with Incubator and CRO Businesses Invests in Seed Stage Therapeutics & Diagnostics Companies

26 Aug

A biotech sector fund with headquarters in China is equipped with state-of-the-art instruments housed by modern laboratories in an artistically designed building. The firm works with top ten largest global pharmaceutical companies and small to medium sized US and Europe-based businesses in studies of gene-to-structure, in vitro and in vivo assays, target ID, ADME, animal models, and more.

The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to tailor its incubator and CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities based in China and North America, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking in-licensing opportunities and plans to make 10-12 investments next year but is flexible.

The firm focuses mostly on therapeutics, while the firm is also open to Diagnostics. The firm can utilize its CRO services to advance portfolio company’s products into or through clinical trials. The firm is currently most interested in small molecule first-in-class drugs. The firm is opportunistic in terms of subsector and indication. For therapeutics, the firm is open to invest from super early-stage to pre-clinical stage. The firm will not invest in Medical Devices Healthcare IT companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: